Blood-to-brain drug delivery using nanocarriers

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 10, Issue , 2014, Pages 433-454

  Gaillard, Pieter J ^a   Visser, Corine C ^a   Boer, Marco De ^a   Appeldoorn, Chantal C M ^a   Rip, Jaap ^a  

^a to BBB technologies BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREMOPHOR; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; INSULIN RECEPTOR; IRINOTECAN; LOPERAMIDE; NANOCARRIER; PACLITAXEL;

ARTICLE; BLOOD BRAIN BARRIER; DRUG APPROVAL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG STABILITY; LIFE EXPECTANCY; LIGHT SCATTERING; NANOENCAPSULATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 85081146359     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9105-7_15     Document Type: Article

References (93)

1. Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, Bhavna (2010) Potential of nanopar-ticulate drug delivery systems by intranasal administration. Curr Pharm Des 16(14): 1644–1653
2. Bankiewicz K (2014) Neurosurgical approaches: drug infusion directly into the parenchyma or cerebrospinal fluid. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York, Chapter 20 of this book
3. Banks WA (2008) Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 90(5):589–594
4. Beg S, Samad A, Alam MI, Nazish I (2011) Dendrimers as novel systems for delivery of neuro-pharmaceuticals to the brain. CNS Neurol Disord Drug Targets 10(5):576–588
5. Bhaskar S, Tian F, Stoeger T et al (2010) Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 7:3
6. Bondi ML, Di Gesu R, Craparo EF (2012) Lipid nanoparticles for drug targeting to the brain. Methods Enzymol 508:229–251
7. Boraschi D, Costantino L, Italiani P (2012) Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine (Lond) 7(1):121–131
8. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P (2009) Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 87(4):212–251
9. Chaurasia CS, Muller M, Bashaw ED et al (2007) AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24(5):1014–1025
10. Costantino L, Boraschi D (2012) Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 17(7–8):367–378
11. Dadparvar M, Wagner S, Wien S, Kufl eitner J, Worek F, von Briesen H, Kreuter J (2011) HI 6human serum albumin nanoparticles–development and transport over an in vitro blood-brain barrier model. Toxicol Lett 206(1):60–66
12. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) PLGA-based nanoparti-cles: an overview of biomedical applications. J Control Release 161(2):505–522
13. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fl uid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691–703
14. de Lange EC, de Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45(2–3):125–148
15. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O (2006) Blood-brain barrier and chemo-therapeutic treatment of brain tumors. Expert Rev Neurother 6(8):1199–1209
16. Deguchi Y (2002) Application of in vivo brain microdialysis to the study of blood-brain barriertransport of drugs. Drug Metab Pharmacokinet 17(5):395–407
17. Deli MA, Abraham CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 25(1):59–127
18. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8(6):2101–2141
19. Fabel K, Dietrich J, Hau P et al (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92(7):1936–1942
20. Farrell D, Ptak K, Panaro NJ, Grodzinski P (2011) Nanotechnology-based cancer therapeutics–promise and challenge–lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm Res 28(2):273–278
21. FDA (2001) Guidance for Industry: S7A Safety Pharmacology Studies for Human Pharmaceuticals.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM074959.pdf
22. FDA (2002) Guidance for Industry: Liposome Drug Products.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pd
23. FDA (2004) Guidance for Industry: Changes to an approved NDA or ANDA. http://www.fda.gov/OHRMS/DOCKETS/98fr/1999d-0529-gdl0003.pdf
24. FDA (2006) Guidance for Industry and FDA Staff: Early Development Considerations for Innovative CombinationProducts.http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126054.pdf
25. FDA (2010) Draft Guidance on Doxorubicin Hydrochloride. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf
26. FDA-CMC Overview of CMC guidances.http://www.fda.gov/Drugs/GuidanceCompliance
27. RegulatoryInformation/Guidances/ucm064979.htm
28. Fernandes C, Soni U, Patravale V (2010) Nano-interventions for neurodegenerative disorders.Pharmacol Res 62(2):166–178
29. Fortin D (2014) Osmotic Opening of the BBB for DRug Treatment for Brain Tumors (Focus on Methodological Issues). In: Hammarlund- Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York,Chapter 21 of this book
30. Gabathuler R (2014) Development of new protein vecotrs for the physiologic delivery of large therapeutic compounds to the CNS. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer,New York, Chapter 18 of this book
31. Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7(2):223–225
32. Gaillard PJ (2010) Crossing barriers from blood-to-brain and academia-to-industry. Ther Deliv1(4):495–500
33. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J (2011) Enhanced brain drug delivery: safely crossing the blood-brain barrier. Drug Discov Today Technol 9(2):e155–e160
34. Gaillard PJ, Gladdines W, Appeldoorn CCM, et al. (2012) Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer. [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 31 Mar–4 Apr; Chicago, Illinois. Philadelphia (PA): AACR; 2012. Abstract nr 5687
35. Ganta S, Deshpande D, Korde A, Amiji M (2010) A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol 27(7):260–273
36. Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ (2009) Effective GDNF brain delivery using microspheres—a promising strategy for Parkinson’s disease. J Control Release 135(2):119–126
37. Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V (2011) Brain-targeted delivery of pacli-taxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 19(9):837–845
38. Gilead Sciences, Inc. (2000) Press Release; http://www.gilead.com/pr_969296575
39. Glas M, Koch H, Hirschmann B et al (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72(5–6):302–307
40. Gray D (2014) Pharmacoeconomical considerations of CNS drug development. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York, Chapter 15 of this book
41. Hammarlund-Udenaes M (2009) Active-site concentrations of chemicals—are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215–220
42. Hammarlund-Udenaes M (2014) PK concepts for brain drug delivery. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York, Chapter 6 of this book
43. Hau P, Fabel K, Baumgart U et al (2004) Pegylated liposomal doxorubicin-effi cacy in patients with recurrent high-grade glioma. Cancer 100(6):1199–1207
44. Helmchen F, Denk W (2005) Deep tissue two-photon microscopy. Nat Methods 2(12):932–940
45. Holmgaard R, Benfeldt E, Nielsen JB et al (2012) Comparison of open-fl ow microperfusion and microdialysis methodologies when sampling topically applied fentanyl and benzoic acid in human dermis ex vivo. Pharm Res 29:1808–1820
46. Jiang W, Lionberger R, Yu LX (2011) In vitro and in vivo characterizations of PEGylated liposo-mal doxorubicin. Bioanalysis 3(3):333–344
47. Jiskoot W, van Schie RM, Carstens MG, Schellekens H (2009) Immunological risk of injectable drug delivery systems. Pharm Res 26(6):1303–1314
48. Jones AR, Shusta EV (2007) Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24(9):1759–1771
49. Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in brain targeting. J Control Release 127(2):97–109
50. Kean T, Thanou M (2010) Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62(1):3–11
51. Kim BY, Rutka JT, Chan WC (2010) Nanomedicine. N Engl J Med 363(25):2434–2443
52. Konofagou EE (2014) Emerging engineering technologies for opening the BBB. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York, Chapter 22 of this book
53. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132(3):171–183
54. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9(1):46–59
55. Lindqvist A, Rip J, Gaillard PJ, Björkman S, Hammarlund-Udenaes M (2012) Enhanced brain delivery of the opioid peptide DAMGO in glutathione PEGylated liposomes: a microdialysis study. Mol Pharm 10:1533–1541
56. Luppi B, Bigucci F, Cerchiara T, Zecchi V (2010) Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin Drug Deliv 7(7):811–828
57. Lutz J, Augustin AJ, Jager LJ, Bachmann D, Brandl M (1995) Acute toxicity and depression of phagocytosis in vivo by liposomes: infl uence of lysophosphatidylcholine. Life Sci 56(2):99–106
58. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14(1):45–53
59. Morigi V, Tocchio A, Pellegrini CB, Sakamoto JH, Arnone M, Tasciotti E (2012) Nanotechnology in medicine: from inception to market domain. J Drug Deliv Article ID 389485, 7 pages. doi:10.1155/2012/389485
60. Mufamadi MS, Pillay V, Choonara YE, Du Toit LC, Modi G, Naidoo D, Ndesendo VM (2011) A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv Article ID 939851, 19 pages. doi:10.1155/2011/939851
61. Muller RH, Keck CM (2012) Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm 80(1):1–3
62. Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58(11):1423–1430
63. Nystrom AM, Fadeel B (2012) Safety assessment of nanomaterials: implications for nanomedi-cine. J Control Release 161(2):403–408
64. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13(6):1656–1662
65. Pardridge WM (2010) Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc (4): pdb prot5407
66. Parnham MJ, Wetzig H (1993) Toxicity screening of liposomes. Chem Phys Lipids 64(1–3): 263–274
67. Patel T, Zhou J, Piepmeier JM, Saltzman WM (2011) Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 64(7):701–705
68. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V (2008) Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 151(2–3):565–577
69. Rempe R, Cramer S, Huwel S, Galla HJ (2011) Transport of Poly(n-butylcyano-acrylate) nanopar-ticles across the blood-brain barrier in vitro and their infl uence on barrier integrity. Biochem Biophys Res Commun 406(1):64–69
70. Rip J, Appeldoorn CC, Manca FM, Dorland R, Van Kregten JM and Gaillard PJ (2010) Receptor-mediated delivery of drugs across the blood-brain barrier. Front. Pharmacol. Conference Abstract: Pharmacology and Toxicology of the Blood-Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. doi: 10.3389/conf.fphar.2010.02.00025
71. Sanhai WR, Sakamoto JH, Canady R, Ferrari M (2008) Seven challenges for nanomedicine. Nat Nanotechnol 3(5):242–244
72. Shih AY, Mateo C, Drew PJ, Tsai PS, Kleinfeld D (2012) A polished and reinforced thinned-skull window for long-term imaging of the mouse brain. J Vis Exp pii (61):3742
73. Smith QR, Allen DD (2003) In situ brain perfusion technique. Methods Mol Med 89:209–218
74. Szebeni J, Alving CR, Baranyi L, Bunger R (2010) Interaction of liposomes with complement leading to adverse reactions. In: Gregoriadis G (ed) Liposome technology—volume III interactions of liposomes with the biological milieu, 3rd edn. Informa Healthcare USA, Inc, Zug
75. Szebeni J, Muggia F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63(12):1020–1030
76. Szebeni J, Bedocs P, Rozsnyay Z et al (2012) Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8(2):176–184
77. Tazina EV, Kostin K V, Oborotova NA (2011) Specifi c features of drug encapsulation in liposomes (a review). Pharm Chem J 45(8):481–490
78. Thorne R (2014) Intranasal drug delivery to the brain. In: Hammarlund-Udenaes M, de Lange E, Thorne R (eds) Drug delivery to the brain—physiological concepts, methodologies and approaches. Springer, New York, Chapter 16 of this book
79. Tsai CS, Park JW, Chen LT (2011) Nanovector-based therapeis in advanced pancreatic cancer. J Gastrointest Oncol 2:185–194
80. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody- modifi ed nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71(2):251–256
81. Ulbrich K, Knobloch T, Kreuter J (2011) Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 19(2):125–132
82. van Rooy I, Cakir-Tascioglu S, Couraud PO et al (2010) Identifi cation of peptide ligands for targeting to the blood-brain barrier. Pharm Res 27(4):673–682
83. van Rooy I, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E (2012) Attaching the phage display-selected GLA peptide to liposomes: factors infl uencing target binding. Eur J Pharm Sci 45(3):330–335
84. Wagner S, Kufl eitner J, Zensi A et al (2010) Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS One 5(12):e14213
85. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 6:765–774
86. Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 71(1):113–128
87. Wilson B (2009) Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine (Lond) 4(5):499–502
88. WMA (2008) World Medical Association Declaration of Helsinki.http://www.wma.net/ en/30publications/10policies/b3/17c.pdf
89. Wohlfart S, Gelperina S, Kreuter J (2011) Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161(2):264–273
90. Wolf SM, Jones CM (2011) Designing oversight for nanomedicine research in human subjects: systematic analysis of exceptional oversight for emerging technologies. J Nanopart Res 13:1449–1465
91. Wong HL, Wu XY, Bendayan R (2011) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64(7):686–700
92. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83(5):761–769
93. Zucker D, Marcus D, Barenholz Y, Goldblum A (2009) Liposome drugs’ loading effi ciency: a working model based on loading conditions and drug's physicochemical properties. J Control Release 139(1):73–80